Zantac (Ranitidine NDMA) (US): Settlement Amounts

Archived

United States case record · Last verified: 2026-09-29

Reported amounts & case results

GSK: up to $2.2 billion for ~80,000 state claims (~93%, per public reports, Oct 2024). Sanofi: up to $350 million (per public reports, May 2024). Federal MDL: dismissed Dec 2022, on appeal (per court records). No new intake.

Figures are as reported by the cited sources — not a promise of any individual outcome.

Reported amounts are what sources say — not a promise. Individual results depend on injuries, jurisdiction, and the stage of the case. This is not legal advice.

What affects case value

Injury severity — the single largest driver across mass torts.
Jurisdiction — national/state/provincial law (e.g., discovery rules, statute of limitations) can change outcomes.
Case stage — early filings and post-bellwether values differ.
Documentation — medical records and the exposure timeline.

Case record — archived

The litigation for this matter has concluded; case reviews are closed. The amounts above are reported figures — not a promise of recovery.